PortalPublikationenComparison of upfront tandem autologous-allogeneic transplan...

Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma

Standard

Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma. / Sahebi, F; Iacobelli, S; Biezen, A V; Volin, L; Dreger, P; Michallet, M; Ljungman, P T; de Witte, T; Henseler, A; Schaap, N P M; López-Corral, L; Poire, X; Passweg, J; Hamljadi, R-M; Thomas, S H; Schonland, S; Gahrton, G; Morris, C; Kröger, N; Garderet, L.

in: BONE MARROW TRANSPL, Jahrgang 50, Nr. 6, 23.03.2015, S. 802-807.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sahebi, F, Iacobelli, S, Biezen, AV, Volin, L, Dreger, P, Michallet, M, Ljungman, PT, de Witte, T, Henseler, A, Schaap, NPM, López-Corral, L, Poire, X, Passweg, J, Hamljadi, R-M, Thomas, SH, Schonland, S, Gahrton, G, Morris, C, Kröger, N & Garderet, L 2015, 'Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma', BONE MARROW TRANSPL, Jg. 50, Nr. 6, S. 802-807. https://doi.org/10.1038/bmt.2015.45

APA

Sahebi, F., Iacobelli, S., Biezen, A. V., Volin, L., Dreger, P., Michallet, M., Ljungman, P. T., de Witte, T., Henseler, A., Schaap, N. P. M., López-Corral, L., Poire, X., Passweg, J., Hamljadi, R-M., Thomas, S. H., Schonland, S., Gahrton, G., Morris, C., Kröger, N., & Garderet, L. (2015). Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma. BONE MARROW TRANSPL, 50(6), 802-807. https://doi.org/10.1038/bmt.2015.45

Vancouver

Sahebi F, Iacobelli S, Biezen AV, Volin L, Dreger P, Michallet M et al. Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma. BONE MARROW TRANSPL. 2015 Mär 23;50(6):802-807. https://doi.org/10.1038/bmt.2015.45

Bibtex

@article{e5d3ee1577654dec9f758ca4bf5514c4,
title = "Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma",
abstract = "We performed a retrospective analysis of the European Group for Blood and Marrow Transplantation database comparing the outcomes of multiple myeloma patients who received tandem autologous followed by allogeneic PSCT (auto-allo) with the outcomes of patients who underwent a reduced intensity conditioning allograft (early RIC) without prior autologous transplant. From 1996 to 2013, we identified a total of 690 patients: 517 patients were planned to receive auto-allo and 173 received an early RIC allograft without prior autologous transplant. With a median follow-up of 93 months, 5-year PFS survival was significantly better in the auto-allo group, 34% compared with 22% in the early RIC group (P<0.001). OS was also significantly improved in the auto-allo group with a 5-year rate of 59% vs 42% in the early RIC group (P=0.001). The non-relapse mortality rate was lower in the auto-allo group than in the early RIC group, with 1- and 3-year rates of 8% and 13% vs 20% and 28%, respectively (P<0.001). The relapse/progression rate was similar in the two groups, with 5-year rates of 50% for auto-allo and 46% for early RIC (P=0.42). These data suggest that planned tandem autologous allograft can improve overall survival compared with upfront RIC allograft alone in patients with multiple myeloma.Bone Marrow Transplantation advance online publication, 23 March 2015; doi:10.1038/bmt.2015.45.",
author = "F Sahebi and S Iacobelli and Biezen, {A V} and L Volin and P Dreger and M Michallet and Ljungman, {P T} and {de Witte}, T and A Henseler and Schaap, {N P M} and L L{\'o}pez-Corral and X Poire and J Passweg and R-M Hamljadi and Thomas, {S H} and S Schonland and G Gahrton and C Morris and N Kr{\"o}ger and L Garderet",
year = "2015",
month = mar,
day = "23",
doi = "10.1038/bmt.2015.45",
language = "English",
volume = "50",
pages = "802--807",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "6",

}

RIS

TY - JOUR

T1 - Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma

AU - Sahebi, F

AU - Iacobelli, S

AU - Biezen, A V

AU - Volin, L

AU - Dreger, P

AU - Michallet, M

AU - Ljungman, P T

AU - de Witte, T

AU - Henseler, A

AU - Schaap, N P M

AU - López-Corral, L

AU - Poire, X

AU - Passweg, J

AU - Hamljadi, R-M

AU - Thomas, S H

AU - Schonland, S

AU - Gahrton, G

AU - Morris, C

AU - Kröger, N

AU - Garderet, L

PY - 2015/3/23

Y1 - 2015/3/23

N2 - We performed a retrospective analysis of the European Group for Blood and Marrow Transplantation database comparing the outcomes of multiple myeloma patients who received tandem autologous followed by allogeneic PSCT (auto-allo) with the outcomes of patients who underwent a reduced intensity conditioning allograft (early RIC) without prior autologous transplant. From 1996 to 2013, we identified a total of 690 patients: 517 patients were planned to receive auto-allo and 173 received an early RIC allograft without prior autologous transplant. With a median follow-up of 93 months, 5-year PFS survival was significantly better in the auto-allo group, 34% compared with 22% in the early RIC group (P<0.001). OS was also significantly improved in the auto-allo group with a 5-year rate of 59% vs 42% in the early RIC group (P=0.001). The non-relapse mortality rate was lower in the auto-allo group than in the early RIC group, with 1- and 3-year rates of 8% and 13% vs 20% and 28%, respectively (P<0.001). The relapse/progression rate was similar in the two groups, with 5-year rates of 50% for auto-allo and 46% for early RIC (P=0.42). These data suggest that planned tandem autologous allograft can improve overall survival compared with upfront RIC allograft alone in patients with multiple myeloma.Bone Marrow Transplantation advance online publication, 23 March 2015; doi:10.1038/bmt.2015.45.

AB - We performed a retrospective analysis of the European Group for Blood and Marrow Transplantation database comparing the outcomes of multiple myeloma patients who received tandem autologous followed by allogeneic PSCT (auto-allo) with the outcomes of patients who underwent a reduced intensity conditioning allograft (early RIC) without prior autologous transplant. From 1996 to 2013, we identified a total of 690 patients: 517 patients were planned to receive auto-allo and 173 received an early RIC allograft without prior autologous transplant. With a median follow-up of 93 months, 5-year PFS survival was significantly better in the auto-allo group, 34% compared with 22% in the early RIC group (P<0.001). OS was also significantly improved in the auto-allo group with a 5-year rate of 59% vs 42% in the early RIC group (P=0.001). The non-relapse mortality rate was lower in the auto-allo group than in the early RIC group, with 1- and 3-year rates of 8% and 13% vs 20% and 28%, respectively (P<0.001). The relapse/progression rate was similar in the two groups, with 5-year rates of 50% for auto-allo and 46% for early RIC (P=0.42). These data suggest that planned tandem autologous allograft can improve overall survival compared with upfront RIC allograft alone in patients with multiple myeloma.Bone Marrow Transplantation advance online publication, 23 March 2015; doi:10.1038/bmt.2015.45.

U2 - 10.1038/bmt.2015.45

DO - 10.1038/bmt.2015.45

M3 - SCORING: Journal article

C2 - 25798673

VL - 50

SP - 802

EP - 807

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 6

ER -